| 产品名称： | Amycolatopsis mediterranei (Margalith and Beretta) Lechevalier et al. |
|---|---|
| 商品货号： | TS176519 |
| Deposited As： | Nocardia mediterranei (Margalith and Beretta) Thiemann et al. |
| Strain Designations： | M-36 |
| Application： | Produces rifamycin P Produces rifamycin Q Produces rifamycin R Produces rifamycin U |
| Isolation： | Mutant derived from ATCC 13685 |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Preceptrol®： | no |
| Type Strain： | no |
| Medium： | ATCC® Medium 196: Yeast malt extract agar |
| Growth Conditions： | Temperature: 26.0°C |
| Name of Depositor： | Gruppo Lepetit S.p.A. |
| U.S. Patent Number： | |
| References： | Martinelli E, et al. Rifamycin R, a novel metabolite from a mutant of Nocardia mediterranea. J. Antibiot. 31: 949-951, 1978. PubMed: 711618 Lancini G, et al. Rifamycins P, Q, and U. US Patent 4,042,683 dated Aug 16 1977 Lechevalier MP, et al. Two new genera of nocardioform Actinomycetes: Amycolata gen. nov. and Amycolatopsis gen. nov.. Int. J. Syst. Bacteriol. 36: 29-37, 1986. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Amycolatopsis mediterranei (Margalith and Beretta) Lechevalier et al. |
|---|---|
| 商品货号： | TS176519 |
| Deposited As： | Nocardia mediterranei (Margalith and Beretta) Thiemann et al. |
| Strain Designations： | M-36 |
| Application： | Produces rifamycin P Produces rifamycin Q Produces rifamycin R Produces rifamycin U |
| Isolation： | Mutant derived from ATCC 13685 |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Preceptrol®： | no |
| Type Strain： | no |
| Medium： | ATCC® Medium 196: Yeast malt extract agar |
| Growth Conditions： | Temperature: 26.0°C |
| Name of Depositor： | Gruppo Lepetit S.p.A. |
| U.S. Patent Number： | |
| References： | Martinelli E, et al. Rifamycin R, a novel metabolite from a mutant of Nocardia mediterranea. J. Antibiot. 31: 949-951, 1978. PubMed: 711618 Lancini G, et al. Rifamycins P, Q, and U. US Patent 4,042,683 dated Aug 16 1977 Lechevalier MP, et al. Two new genera of nocardioform Actinomycetes: Amycolata gen. nov. and Amycolatopsis gen. nov.. Int. J. Syst. Bacteriol. 36: 29-37, 1986. |
